S1PR1 serves as a viable drug target against pulmonary fibrosis by increasing the integrity of the endothelial barrier of the lung
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with unclear etiology and limited treatment options. The median survival time for IPF patients is approximately 2-3 years and there is no effective intervention to treat IPF other than lung transplantation. As important components of...
Furkejuvvon:
Váldodahkkit: | , , , , , , , , , , , , , , , |
---|---|
Materiálatiipa: | Girji |
Almmustuhtton: |
Elsevier,
2023-03-01T00:00:00Z.
|
Fáttát: | |
Liŋkkat: | Connect to this object online. |
Fáddágilkorat: |
Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
Interneahtta
Connect to this object online.3rd Floor Main Library
Hildobáiki: |
A1234.567 |
---|---|
Njađus 1 | Oažžumis |